According to LeMaitre Vascular's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 40.8267. At the end of 2024 the company had a P/E ratio of 46.8.
Year | P/E ratio | Change |
---|---|---|
2024 | 46.8 | 11.24% |
2023 | 42.0 | -13.21% |
2022 | 48.4 | 22.48% |
2021 | 39.6 | 2.54% |
2020 | 38.6 | -3.44% |
2019 | 39.9 | 99.38% |
2018 | 20.0 | -43.37% |
2017 | 35.4 | -20.42% |
2016 | 44.5 | 13.4% |
2015 | 39.2 | 17.87% |
2014 | 33.3 | -8.65% |
2013 | 36.4 | 7.83% |
2012 | 33.8 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() AngioDynamics ANGO | -9.03 | -122.12% | ๐บ๐ธ USA |
![]() Boston Scientific BSX | 76.7 | 87.86% | ๐บ๐ธ USA |
![]() Edwards Lifesciences EW | 11.2 | -72.57% | ๐บ๐ธ USA |
![]() Cardiovascular Systems CSII | -20.6 | -150.50% | ๐บ๐ธ USA |
![]() Teleflex TFX | 36.0 | -11.82% | ๐บ๐ธ USA |
![]() Baxter BAX | -951 | -2,428.54% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.